Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Mantle Cell Lymphoma Resource Center

News
Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features
02/14/2024

Grace Taylor

Grace Taylor
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024

Featuring Eliza A Hawkes, MD

Featuring Eliza A Hawkes, MD
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
From Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024

Featuring Bijal D. Shah, MD

Featuring Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
From Oncology
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022

Katie Herman 

Katie Herman 
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways
Tycel Phillips, MD
Videos
Frontline Therapies for Patients With Untreated and Relapsed Mantle Cell Lymphoma
09/14/2022
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews...
09/14/2022
Journal of Clinical Pathways
News
Study Indicates Late Effects in Mantle Cell Lymphoma Treatment With or Without Transplantation Have Minimal Impact
09/12/2022

Yvette C Terrie

Yvette C Terrie
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study...
09/12/2022
Journal of Clinical Pathways
News
Exploring Radiation Therapy for Orbital Involvement in Patients with Mantle Cell Lymphoma
09/12/2022

Yvette C Terrie

Yvette C Terrie
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic...
09/12/2022
Journal of Clinical Pathways
News
Exploring PD-1/PD-L1 Expression in Mantle Cell Lymphoma and its Significance as an Immune Check Point Inhibitor
08/26/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study...
08/26/2022
Journal of Clinical Pathways
News
Autologous Stem-Cell Transplant Underutilized Among Patients With Mantle Cell Lymphoma in US Community Settings
08/16/2022

Yvette C Terrie

Yvette C Terrie
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among...
08/16/2022
Journal of Clinical Pathways
News
Survey Explores Prescriber Perceptions and Preferences Regarding First Line Therapy for MCL
07/27/2022

Ellen Kurek

Ellen Kurek
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line...
07/27/2022
Journal of Clinical Pathways

Expert Insights

Eliza A Hawkes, MD
Videos
Promising Advances in the Mantle Cell Lymphoma Treatment Landscape
02/13/2024

Featuring Eliza A Hawkes, MD

Featuring Eliza A Hawkes, MD
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.
Eliza A Hawkes, MD, shares some...
02/13/2024
Oncology
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024

Featuring Bijal D. Shah, MD

Featuring Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Tycel Phillips, MD
Videos
Frontline Therapies for Patients With Untreated and Relapsed Mantle Cell Lymphoma
09/14/2022
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews standard therapies utilized for patients with mantle cell lymphoma, including nonaggressive regimens and BTK inhibitor therapies.
Tycel Phillips, MD, reviews...
09/14/2022
Journal of Clinical Pathways
Mayur Narkhede, MD
Videos
Real-World Treatment Patterns and Outcomes Among Patients With Mantle Cell Lymphoma
07/21/2022
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed treatment patterns among patients with mantle cell lymphoma at different lines of therapy, focusing on BTKi use, and compared outcomes with known prognostic factors.
Mayur Narkhede, MD, analyzed...
07/21/2022
Journal of Clinical Pathways
Real-World Practice Patterns and Predictors of Survival in Older Patients With MCL
ENGAGING EXPERTS
Real-World Practice Patterns and Predictors of Survival in Older Patients With MCL
01/15/2021
David Bond, MD, discusses results from a real-world study highlighting risk factors, clinical outcomes, andpredictors of survival in older patients with MCL treated in the rituximab era.
David Bond, MD, discusses results from a real-world study highlighting risk factors, clinical outcomes, andpredictors of survival in older patients with MCL treated in the rituximab era.
David Bond, MD, discusses...
01/15/2021
Journal of Clinical Pathways
Novel BTK Inhibitor Promising for Mantle Cell Lymphoma
ENGAGING EXPERTS
Novel BTK Inhibitor Promising for Mantle Cell Lymphoma
06/23/2020
Peter Martin, MD, Weill Cornell Medicine, New York, New York, discusses the data that led to the recent accelerated approval of zanubrutinib for the treatment of patients with mantle cell lymphoma.
Peter Martin, MD, Weill Cornell Medicine, New York, New York, discusses the data that led to the recent accelerated approval of zanubrutinib for the treatment of patients with mantle cell lymphoma.
Peter Martin, MD, Weill Cornell...
06/23/2020
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Newsfeed

News
Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features
02/14/2024

Grace Taylor

Grace Taylor
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Bijal Shah, MD
Conference Coverage
Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape
01/08/2024

Featuring Bijal D. Shah, MD

Featuring Bijal D. Shah, MD
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.
Bijal D. Shah, MD, shares the...
01/08/2024
Oncology
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022

Katie Herman 

Katie Herman 
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways
News
Study Indicates Late Effects in Mantle Cell Lymphoma Treatment With or Without Transplantation Have Minimal Impact
09/12/2022

Yvette C Terrie

Yvette C Terrie
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...
Results from a recent study...
09/12/2022
Journal of Clinical Pathways
News
Exploring Radiation Therapy for Orbital Involvement in Patients with Mantle Cell Lymphoma
09/12/2022

Yvette C Terrie

Yvette C Terrie
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.
Mantle cell lymphoma with optic...
09/12/2022
Journal of Clinical Pathways
News
Exploring PD-1/PD-L1 Expression in Mantle Cell Lymphoma and its Significance as an Immune Check Point Inhibitor
08/26/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.
Findings from a recent study...
08/26/2022
Journal of Clinical Pathways
News
Autologous Stem-Cell Transplant Underutilized Among Patients With Mantle Cell Lymphoma in US Community Settings
08/16/2022

Yvette C Terrie

Yvette C Terrie
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...
Study findings reveal that among...
08/16/2022
Journal of Clinical Pathways
News
Survey Explores Prescriber Perceptions and Preferences Regarding First Line Therapy for MCL
07/27/2022

Ellen Kurek

Ellen Kurek
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line...
07/27/2022
Journal of Clinical Pathways
News
Evaluating Attrition Rates and Treatment Outcomes Among Patients With MCL
07/14/2022

Ellen Kurek

Ellen Kurek
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.
Findings from a recent...
07/14/2022
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns and Efficacy of Bruton Tyrosine Kinase Inhibitors in Patients With MCL
06/09/2022

Robert Fee

Robert Fee
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network assessed treatment patterns and associated outcomes in patients with MCL who were treated with BTKi.
Retrospective multicenter chart...
06/09/2022
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
Conference Coverage
Cybersecurity, Drug Shortages, and PBMs: Legislative Updates Impacting Oncology
04/12/2024

Grace Taylor

Grace Taylor
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry experts recently shared legislative updates from Washington, DC, impacting oncology at the 2024 Community Oncology Conference.
A group of health care industry...
04/12/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Survival Outcomes in Patients With MCL Treated With Bruton Tyrosine Kinase Inhibitors
04/12/2022
True or False: BTK inhibitors in the second-line setting improve overall survival and lymphoma-specific survival among patients with MCL.
True or False: BTK inhibitors in the second-line setting improve overall survival and lymphoma-specific survival among patients with MCL.
True or False: BTK inhibitors in...
04/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Treatment Patterns for MCL
01/20/2022
True or False: Bendamustine plus rituximab is the most commonly used first-line treatment for MCL in the US, while receipt of stem cell transplant is uncommon.
True or False: Bendamustine plus rituximab is the most commonly used first-line treatment for MCL in the US, while receipt of stem cell transplant is uncommon.
True or False: Bendamustine plus...
01/20/2022
Journal of Clinical Pathways
Quiz
Quiz: Rituximab Among Older Patients With MCL
09/03/2021
True or False: Older patients with MCL may not benefit from maintenance rituximab, due to an inability to tolerate this treatment.
True or False: Older patients with MCL may not benefit from maintenance rituximab, due to an inability to tolerate this treatment.
True or False: Older patients...
09/03/2021
Journal of Clinical Pathways
Quiz
Quiz: Impact of Comorbidities on Treatment Choices for Older Patients With MCL
04/28/2021
04/28/2021
Journal of Clinical Pathways
Quiz
Quiz: Is KTE-X19 a Cost-Effective Treatment for MCL?
04/23/2021
04/23/2021
Journal of Clinical Pathways
Quiz
Quiz: MRD Status for Patients With MCL
03/08/2021
03/08/2021
Journal of Clinical Pathways
Quiz
Quiz: Is Pre-Transplant MRD Status Predictive of Survival in MCL?
02/16/2021
02/16/2021
Journal of Clinical Pathways
Quiz
Quiz: Economic Burden of MCL in the VHA Population
09/29/2020
09/29/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement